Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Peginterferon Alfa-2a · Pegasys

Recombinant protein · Immune activation, directed at Interferon alpha/beta receptor · developed by Pharmaand Gmbh

Approved FDA, Oct 2002
1 Registered trials

What is Peginterferon Alfa-2a?

Peginterferon Alfa-2a is a covalent conjugate of recombinant interferon alfa-2a and polyethylene glycol. It binds cell-surface interferon receptors to induce the innate antiviral immune response, and is used in chronic hepatitis C and chronic hepatitis B.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pegasys, pegylated interferon-alfa 2a
Drug type
Recombinant protein
Targets
Interferon alpha/beta receptor
Mechanism
Immune activation, directed at Interferon alpha/beta receptor
Pathways
innate antiviral immune response, antiviral, antiproliferative and immune-modulating gene transcription
Therapy area
Gastroenterology, Infectious disease
Developer
Pharmaand Gmbh
In trials of
ALNY
FDA status
Approved as Pegasys (October 16, 2002), BLA103964 · FDA label
UNII
Q46947FE7K

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 2, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04412863 Phase 2 Chronic Hepatitis B Completed ALNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.